Home >> Signaling Pathways >> JAK/STAT Signaling

JAK/STAT Signaling

Targets for  JAK/STAT Signaling

Products for  JAK/STAT Signaling

  1. Cat.No. Product Name Information
  2. GC38081 Theliatinib Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. Theliatinib has an IC50 of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases. Anti-tumor activity. Theliatinib  Chemical Structure
  3. GC19361 TP-3654 TP-3654 is a second-generation Pim kinase inhibitor with Ki values of 5 and 42 nM for Pim-1 and Pim-3, respectively. TP-3654  Chemical Structure
  4. GC17621 TPCA-1 A selective inhibitor of IKK2 TPCA-1  Chemical Structure
  5. GC34215 Trastuzumab (Anti-Human HER2, Humanized Antibody) Trastuzumab (Anti-Human HER2, Humanized Antibody) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (Anti-Human HER2, Humanized Antibody) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research. Trastuzumab (Anti-Human HER2, Humanized Antibody)  Chemical Structure
  6. GC32726 Tucatinib (Irbinitinib) Tucatinib (Irbinitinib) (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM. Tucatinib (Irbinitinib)  Chemical Structure
  7. GC34847 TX1-85-1 An ErbB3 inhibitor TX1-85-1  Chemical Structure
  8. GC31668 TYK2-IN-2 TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC50s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively. TYK2-IN-2  Chemical Structure
  9. GC32052 Tyk2-IN-3 Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC50 of 485 nM. Tyk2-IN-3  Chemical Structure
  10. GC31659 Tyk2-IN-4 (BMS-986165) Tyk2-IN-4 (BMS-986165) (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Tyk2-IN-4 (BMS-986165)  Chemical Structure
  11. GC65387 Tyk2-IN-5 Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active Tyk2 inhibitor and targets the JH2 domain, with a Ki of 0.086 nM for Tyk2 JH2 and an IC50 of 25 nM for IFNα. Tyk2-IN-5  Chemical Structure
  12. GC37846 Tyk2-IN-7 Tyk2-IN-7 (Compound 48) is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki. Tyk2-IN-7  Chemical Structure
  13. GC37847 Tyk2-IN-8 Tyk2-IN-8 (Compound 3) is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8  Chemical Structure
  14. GC19364 Tyrphostin AG 528 Tyrphostin AG 528 is an inhibitor of EGFR and ErbB2 with IC50s of 4.9 and 2.1 uM, respectively. Tyrphostin AG 528  Chemical Structure
  15. GC15271 Tyrphostin AG 879 HER2 inhibitor Tyrphostin AG 879  Chemical Structure
  16. GC38125 Tyrphostin AG30 Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts. Tyrphostin AG30  Chemical Structure
  17. GC19368 Upadacitinib Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders. Upadacitinib  Chemical Structure
  18. GC12249 Varlitinib (ARRY334543) Varlitinib (ARRY334543) (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively. Varlitinib (ARRY334543)  Chemical Structure
  19. GN10282 Vitexicarpin (Casticin) Vitexicarpin (Casticin)  Chemical Structure
  20. GC67867 VVD-118313 VVD-118313  Chemical Structure
  21. GC40761 VX-509 VX-509 is a selective inhibitor of Janus kinase 3 (JAK3) with a Ki value of 2.5 nM in enzyme assays and an IC50 value of 50-170 nM in cellular assays dependent on JAK3 activity with no measurable activity against other JAK isotypes. VX-509  Chemical Structure
  22. GC70140 W1131

    W1131 is an effective STAT3 inhibitor that can induce ferroptosis. W1131 inhibits cancer progression in gastric cancer subcutaneous xenograft models, organoid models, and PDX models. W1131 effectively reduces chemoresistance of cancer cells to 5-FU. W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation pathways including the IL6-JAK-STAT3 pathway and ferroptosis pathway.

    W1131  Chemical Structure
  23. GC16000 WHI-P180 EGFR/Janus Kinase 3 inhibitor WHI-P180  Chemical Structure
  24. GC37933 WHI-P180 hydrochloride WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 hydrochloride  Chemical Structure
  25. GC15980 WP1066

    An inhibitor of STAT3

    WP1066  Chemical Structure
  26. GC13213 WZ3146 Mutant EGFR inhibitor, potent and irreversible WZ3146  Chemical Structure
  27. GC15494 WZ4002 Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent WZ4002  Chemical Structure
  28. GC11250 WZ8040 EGFR T790M inhibitor,irreversible amd potent WZ8040  Chemical Structure
  29. GC64891 YM-341619 YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC50 of 0.70 nM. YM-341619  Chemical Structure
  30. GC70164 Zalutumumab

    Zalutumumab is a highly affinity pure human IgG1 monoclonal antibody that targets EGFR. Zalutumumab binds to domain III of the epidermal growth factor receptor, exerting its effects by blocking the binding of epidermal growth factor and interfering with the receptor's active conformation. The EC50 values for Zalutumumab with IgG and its Fab regions are 7 and 19 nM, respectively. Zalutumumab can be used in cancer research.

    Zalutumumab  Chemical Structure
  31. GC70165 Zanidatamab

    Zanidatamab (ZW25) is a human bispecific monoclonal antibody targeting 2 different HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumor activity.

    Zanidatamab  Chemical Structure
  32. GC33171 ZD-4190 ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer. ZD-4190  Chemical Structure
  33. GC70169 Zenocutuzumab

    Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody that contains two different Fab arms targeting the extracellular domains of HER2 and HER3.

    Zenocutuzumab  Chemical Structure
  34. GC37971 ZM39923 ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM. ZM39923  Chemical Structure

Items 301 to 333 of 333 total

per page
  1. 1
  2. 2
  3. 3
  4. 4

Set Descending Direction